We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

CervoMed Inc (CRVO) USD0.001

Sell:$18.70 Buy:$19.77 Change: $0.99 (5.50%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.99 (5.50%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.99 (5.50%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. It is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. It is being evaluated in its ongoing RewinD-LB Trial, a Phase 2b study in patients with DLB.

Contact details

20 Park Plaza, Suite 424
United States
+1 (617) 7444400

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$131.65 million
Shares in issue:
8.25 million
United States
US dollar

Key personnel

  • Joshua Boger
    Chairman of the Board
  • John Alam
    President, Chief Executive Officer, Director
  • William Elder
    Chief Financial Officer, General Counsel, Corporate Secretary
  • Robert Cobuzzi
    Chief Operating Officer, Director
  • Kelly Blackburn
    Senior Vice President - Clinical Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.